var data={"title":"Ofloxacin (ophthalmic): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ofloxacin (ophthalmic): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/390297?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ofloxacin-ophthalmic-drug-information\" class=\"drug drug_general\">see &quot;Ofloxacin (ophthalmic): Drug information&quot;</a> and <a href=\"topic.htm?path=ofloxacin-ophthalmic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ofloxacin (ophthalmic): Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9496344\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Ocuflox</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9496345\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Ofloxacin;</li>\n      <li>Ocuflox;</li>\n      <li>PMS-Ofloxacin;</li>\n      <li>Sandoz-Ofloxacin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10512881\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Ophthalmic</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Quinolone</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10512928\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=ofloxacin-ophthalmic-drug-information\" class=\"drug drug_general\">see &quot;Ofloxacin (ophthalmic): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bacterial conjunctivitis:</b> Children and Adolescents: Ophthalmic: Initial: Instill 1 to 2 drops in affected eye(s) every 2 to 4 hours for the first 2 days (Days 1 and 2); then instill 1 to 2 drops 4 times daily for an additional 5 days (Days 3 through 7)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Corneal ulcer</b>: Children and Adolescents: Ophthalmic: Initial: Instill 1 to 2 drops in affected eye(s) every 30 minutes while awake and every 4 to 6 hours at night for the first 2 days (Days 1 and 2); then instill 1 to 2 drops every hour while awake for 4 to 6 additional days (Days 3 through 7 to 9); thereafter, 1 to 2 drops 4 times daily until clinical cure is achieved</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bacterial conjunctivitis:</b> Ophthalmic: Instill 1 to 2 drops in affected eye(s) every 2 to 4 hours for the first 2 days; then instill 1 to 2 drops 4 times daily for an additional 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Corneal ulcer:</b> Ophthalmic: Instill 1 to 2 drops in affected eye(s) every 30 minutes while awake and every 4 to 6 hours after retiring for the first 2 days; beginning on day 3, instill 1 to 2 drops every hour while awake for 4 to 6 additional days; thereafter, 1 to 2 drops 4 times daily until clinical cure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b>Children, Adolescents, and Adults: There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment is unlikely due to low systemic absorption.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment: </b>Children, Adolescents, and Adults: There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment is unlikely due to low systemic absorption.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9497993\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Ophthalmic: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ocuflox: 0.3% (5 mL) [contains benzalkonium chloride]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.3% (5 mL, 10 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9496351\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10512929\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">For ophthalmic use only; not for subconjunctival or direct injection into the anterior chamber of the eye. To avoid excessive systemic absorption, apply gentle pressure to lacrimal sac during and immediately following instillation (1 minute) or instruct patient to gently close eyelid after administration (Urtti 1993; Zimmerman 1984). Avoid touching tip of applicator to eye, fingers, or other surfaces.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9497692\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Store 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10512885\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Treatment of bacterial conjunctivitis caused by <i>Staphylococcus aureus</i>, <i>Staphylococcus epidermidis</i>, <i>Streptococcus pneumoniae, Enterobacter cloacae</i>, <i>Haemophilus influenzae</i>, <i>Proteus mirabilis</i>, and <i>Pseudomonas aeruginosa</i> (FDA approved in ages &ge;1 year and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Treatment of corneal ulcers caused by<i> S. aureus</i>, <i>S</i>. <i>epidermidis</i>, <i>S</i>. <i>pneumoniae, P. aeruginosa</i>, <i>Serratia marcescens, </i>and <i>Cutibacterium acnes</i> (FDA approved in ages &ge;1 year and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9496302\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Ocuflox may be confused with Occlusal-HP, Ocufen</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9497571\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Dizziness, foreign body sensation of eye</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Nausea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision, burning sensation of eyes, conjunctivitis (chemical), eye discomfort, eye pain, eye pruritus, eye redness, keratitis (chemical), lacrimation, photophobia, stinging of eyes, swelling of eye, xerophthalmia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Stevens-Johnson syndrome, toxic epidermal necrolysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9497556\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to ofloxacin, other quinolones, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9497557\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Rare severe hypersensitivity reactions (some fatal), including anaphylaxis and anaphylactic shock, have occurred with systemic quinolone therapy (some following the first dose). Some reactions were accompanied by airway obstruction, angioedema (laryngeal, pharyngeal, or facial edema), cardiovascular collapse, dyspnea, loss of consciousness, pruritus, and urticaria. Discontinue treatment if an allergic reaction occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection. If superinfection is suspected, institute appropriate alternative therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tendon inflammation/rupture: There have been reports of tendon inflammation and/or rupture with systemic quinolone antibiotics. Exposure following ophthalmic administration is substantially lower than with systemic therapy. Discontinue at first sign of tendon inflammation or pain.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Not for subconjunctival injection or for introduction into the ocular anterior chamber.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Special populations: </b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Contact lens wearers: Contact lenses should not be worn during treatment of ophthalmic infections.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299782\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9497684\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=16031&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9496364\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9775998\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies. When administered orally, ofloxacin crosses the placenta (Giamarellou 1989). The amount of ofloxacin available systemically following topical application of the ophthalmic drops is significantly less in comparison to oral doses. If ophthalmic agents are needed during pregnancy, the minimum effective dose should be used in combination with punctual occlusion for 3 to 5 minutes after application to decrease potential exposure to the fetus (Samples 1988).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10512930\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Slit-lamp biomicroscopy and fluorescein staining may be necessary </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9497828\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Ofloxacin is a DNA gyrase inhibitor. DNA gyrase is an essential bacterial enzyme that maintains the superhelical structure of DNA. DNA gyrase is required for DNA replication and transcription, DNA repair, recombination, and transposition; bactericidal</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9775995\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Only small amounts are absorbed systemically after ophthalmic instillation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9497995\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ocuflox Ophthalmic)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.3% (5 mL): $141.78</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ofloxacin Ophthalmic)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.3% (5 mL): $24.53</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961996\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aflacin (SG);</li>\n      <li>Dong Kang Ming (CN);</li>\n      <li>Exocin (DK, ES, FI, GB, GR, IE, IT, PK, PT, TR, ZA, ZW);</li>\n      <li>Exocine (FR);</li>\n      <li>Floksal (UA);</li>\n      <li>Floxal (AT, BG, CH, CZ, DE, HN, PL, RO, RU);</li>\n      <li>Floxedol (ET);</li>\n      <li>Inoflox (PH);</li>\n      <li>Ocuflox (AU, KR, NZ);</li>\n      <li>Oflacin (VN);</li>\n      <li>Oflovid (TW, VN);</li>\n      <li>Oflox (AE, AR, BR, CL, CO, IL, PE, QA, VE);</li>\n      <li>Ofloxin (BG);</li>\n      <li>Ofus (HK);</li>\n      <li>Ofven (IN);</li>\n      <li>Operan (KR);</li>\n      <li>Optiflox (AE, BH, JO, KW, LB, QA);</li>\n      <li>Otoflox (LK);</li>\n      <li>Oxacin (AE);</li>\n      <li>Poenflox (VE);</li>\n      <li>Quinovid (KR);</li>\n      <li>Tarivid (CN, ID, KR, MY, QA, TH);</li>\n      <li>Telbit (KR);</li>\n      <li>Trafloxal (BE, NL);</li>\n      <li>Uniflox (HR);</li>\n      <li>Vista (BD);</li>\n      <li>Ximex Koniflox (ID)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Giamarellou H, Kolokythas E, Petrikkos G, et al. &quot;Pharmacokinetics of Three Newer Quinolones in Pregnant and Lactating Women,&quot; Ciprofloxacin: major advances in intravenous and oral quinolone therapy. Proceedings of a symposium. April 28 to 29, 1989, Naples, Florida.<i> Am J Med</i>. 1989; 87(5A):49S-51S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ofloxacin-ophthalmic-pediatric-drug-information/abstract-text/2589353/pubmed\" target=\"_blank\" id=\"2589353\">2589353</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ocuflox solution (ofloxacin ophthalmic) [prescribing information]. Irvine, CA: Allergan; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Samples JR, Meyer SM. Use of ophthalmic medications in pregnant and nursing women. <i>Am J Ophthalmol</i>. 1988;106(5):616-623.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ofloxacin-ophthalmic-pediatric-drug-information/abstract-text/2903673 /pubmed\" target=\"_blank\" id=\"2903673 \">2903673 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Urtti A, Salminen L. Minimizing systemic absorption of topically administered ophthalmic drugs. <i>Surv Ophthalmol</i>. 1993;37(6):435-456.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ofloxacin-ophthalmic-pediatric-drug-information/abstract-text/8100087/pubmed\" target=\"_blank\" id=\"8100087\">8100087</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zimmerman TJ, Kooner KS, Kandarakis AS, Ziegler LP. Improving the therapeutic index of topically applied ocular drugs.<i> Arch Ophthalmol</i>. 1984;102(4):551-553.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ofloxacin-ophthalmic-pediatric-drug-information/abstract-text/6704011/pubmed\" target=\"_blank\" id=\"6704011\">6704011</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 16031 Version 104.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F9496344\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F9496345\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F10512881\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F10512928\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F9497993\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F9496351\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F10512929\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F9497692\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F10512885\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F9496302\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F9497571\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F9497556\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F9497557\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299782\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F9497684\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F9496364\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F9775998\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F10512930\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F9497828\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F9775995\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F9497995\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961996\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/16031|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ofloxacin-ophthalmic-drug-information\" class=\"drug drug_general\">Ofloxacin (ophthalmic): Drug information</a></li><li><a href=\"topic.htm?path=ofloxacin-ophthalmic-patient-drug-information\" class=\"drug drug_patient\">Ofloxacin (ophthalmic): Patient drug information \t</a></li></ul></div></div>","javascript":null}